Novartis AG (NVS) Shares are Down -2.5%

Novartis AG (NVS) : During the past 4 weeks, traders have been relatively bearish on Novartis AG (NVS), hence the stock is down -4.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.85% relative to the S&P 500. The 4-week change in the price of the stock is -4.74% and the stock has fallen -2.5% in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 3.37% and the fifty day Moving Average is 2.73%. Novartis AG has dropped 1% during the last three month period . Year-to-Date the stock performance stands at -4.23%.

Novartis AG (NVS) : Currently there are 4 street experts covering Novartis AG (NVS) stock. The most bullish and bearish price target for the stock is $115 and $84 respectively for the short term. The average price target of all the analysts comes to $92.75. The estimated standard deviation from the target is $14.86.


Novartis AG (NYSE:NVS): On Fridays trading session , Opening price of the stock was $79.37 with an intraday high of $80.38. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $79.015. However, the stock managed to close at $79.31, a loss of 0.30% for the day. On the previous day, the stock had closed at $79.55. The total traded volume of the day was 1,485,489 shares.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.